Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 120 of 173 entries
Sorted by: Best Match Show Resources per page
Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes.

Environment international

Haenni M, Dagot C, Chesneau O, Bibbal D, Labanowski J, Vialette M, Bouchard D, Martin-Laurent F, Calsat L, Nazaret S, Petit F, Pourcher AM, Togola A, Bachelot M, Topp E, Hocquet D.
PMID: 34923370
Environ Int. 2021 Dec 16;159:107047. doi: 10.1016/j.envint.2021.107047. Epub 2021 Dec 16.

Antimicrobial resistance (AMR) is a major global public health concern, shared by a large number of human and animal health actors. Within the framework of a One Health approach, actions should be implemented in the environmental realm, as well...

Cite
Haenni M, Dagot C, Chesneau O, et al. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environ Int. 2021;159:107047doi: 10.1016/j.envint.2021.107047.
Haenni, M., Dagot, C., Chesneau, O., Bibbal, D., Labanowski, J., Vialette, M., Bouchard, D., Martin-Laurent, F., Calsat, L., Nazaret, S., Petit, F., Pourcher, A. M., Togola, A., Bachelot, M., Topp, E., & Hocquet, D. (2021). Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environment international, 159107047. https://doi.org/10.1016/j.envint.2021.107047
Haenni, Marisa, et al. "Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes." Environment international vol. 159 (2021): 107047. doi: https://doi.org/10.1016/j.envint.2021.107047
Haenni M, Dagot C, Chesneau O, Bibbal D, Labanowski J, Vialette M, Bouchard D, Martin-Laurent F, Calsat L, Nazaret S, Petit F, Pourcher AM, Togola A, Bachelot M, Topp E, Hocquet D. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environ Int. 2021 Dec 16;159:107047. doi: 10.1016/j.envint.2021.107047. Epub 2021 Dec 16. PMID: 34923370.
Copy Download .nbib Format: NLM
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;55:101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 55101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. 55 (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941; PMCID: PMC8732793.
Copy Download .nbib Format: NLM
ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective treatment for chronic myeloid leukemia (CML) and discontinuation of TKI therapy is now being proposed to patients with deep molecular responses. However, evidence demonstrating that TKI are unable to...

Cite
Trinh A, Khamari R, Fovez Q, et al. ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Mol Metab. 2021;101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular metabolism, 101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS." Molecular metabolism vol. (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941.
Copy Download .nbib Format: NLM
Brain readiness and the nature of language.

Frontiers in psychology

Bouchard D.
PMID: 26441751
Front Psychol. 2015 Sep 09;6:1376. doi: 10.3389/fpsyg.2015.01376. eCollection 2015.

To identify the neural components that make a brain ready for language, it is important to have well defined linguistic phenotypes, to know precisely what language is. There are two central features to language: the capacity to form signs...

Cite
Bouchard D. Brain readiness and the nature of language. Front Psychol. 2015;6:1376doi: 10.3389/fpsyg.2015.01376.
Bouchard, D. (2015). Brain readiness and the nature of language. Frontiers in psychology, 61376. https://doi.org/10.3389/fpsyg.2015.01376
Bouchard, Denis. "Brain readiness and the nature of language." Frontiers in psychology vol. 6 (2015): 1376. doi: https://doi.org/10.3389/fpsyg.2015.01376
Bouchard D. Brain readiness and the nature of language. Front Psychol. 2015 Sep 09;6:1376. doi: 10.3389/fpsyg.2015.01376. eCollection 2015. PMID: 26441751; PMCID: PMC4563876.
Copy Download .nbib Format: NLM
Moderate mitral regurgitation at the time of coronary bypass surgery: repair or leave it?.

Current opinion in cardiology

Mazine A, Bouchard D.
PMID: 25574897
Curr Opin Cardiol. 2015 Mar;30(2):133-139. doi: 10.1097/HCO.0000000000000146.

PURPOSE OF REVIEW: Moderate ischemic mitral regurgitation (IMR) is a common finding in patients undergoing coronary artery bypass grafting (CABG). In this review, we summarize the current evidence on the optimal management of this condition.RECENT FINDINGS: In recent years,...

Cite
Mazine A, Bouchard D. Moderate mitral regurgitation at the time of coronary bypass surgery: repair or leave it?. Curr Opin Cardiol. 2015;30(2):133-139doi: 10.1097/HCO.0000000000000146.
Mazine, A., & Bouchard, D. (2015). Moderate mitral regurgitation at the time of coronary bypass surgery: repair or leave it?. Current opinion in cardiology, 30(2), 133-139. https://doi.org/10.1097/HCO.0000000000000146
Mazine, Amine, and Bouchard, Denis. "Moderate mitral regurgitation at the time of coronary bypass surgery: repair or leave it?." Current opinion in cardiology vol. 30,2 (2015): 133-139. doi: https://doi.org/10.1097/HCO.0000000000000146
Mazine A, Bouchard D. Moderate mitral regurgitation at the time of coronary bypass surgery: repair or leave it?. Curr Opin Cardiol. 2015 Mar;30(2):133-139. doi: 10.1097/HCO.0000000000000146. PMID: 25574897.
Copy Download .nbib Format: NLM
Sutureless Aortic Valve Replacement International Registry (SU-AVR-IR): design and rationale from the International Valvular Surgery Study Group (IVSSG).

Annals of cardiothoracic surgery

Di Eusanio M, Phan K, Bouchard D, Carrel TP, Dapunt OE, Di Bartolomeo R, Eichstaedt HC, Fischlein T, Folliguet T, Gersak B, Glauber M, Haverich A, Misfeld M, Oberwalder PJ, Santarpino G, Shrestha ML, Solinas M, Vola M, Alamanni F, Albertini A, Bhatnagar G, Carrier M, Clark S, Collart F, Kappert U, Kocher A, Meuris B, Mignosa C, Ouda A, Pelletier M, Rahmanian PB, Reineke D, Teoh K, Troise G, Villa E, Wahlers T, Yan TD.
PMID: 25870808
Ann Cardiothorac Surg. 2015 Mar;4(2):131-9. doi: 10.3978/j.issn.2225-319X.2015.02.05.

BACKGROUND: Sutureless aortic valve replacement (SU-AVR) is an innovative approach which shortens cardiopulmonary bypass and cross-clamp durations and may facilitate minimally invasive approach. Evidence outlining its safety, efficacy, hemodynamic profile and potential complications is replete with small-volume observational studies...

Cite
Di Eusanio M, Phan K, Bouchard D, et al. Sutureless Aortic Valve Replacement International Registry (SU-AVR-IR): design and rationale from the International Valvular Surgery Study Group (IVSSG). Ann Cardiothorac Surg. 2015;4(2):131-9doi: 10.3978/j.issn.2225-319X.2015.02.05.
Di Eusanio, M., Phan, K., Bouchard, D., Carrel, T. P., Dapunt, O. E., Di Bartolomeo, R., Eichstaedt, H. C., Fischlein, T., Folliguet, T., Gersak, B., Glauber, M., Haverich, A., Misfeld, M., Oberwalder, P. J., Santarpino, G., Shrestha, M. L., Solinas, M., Vola, M., Alamanni, F., Albertini, A., Bhatnagar, G., Carrier, M., Clark, S., Collart, F., Kappert, U., Kocher, A., Meuris, B., Mignosa, C., Ouda, A., Pelletier, M., Rahmanian, P. B., Reineke, D., Teoh, K., Troise, G., Villa, E., Wahlers, T., & Yan, T. D. (2015). Sutureless Aortic Valve Replacement International Registry (SU-AVR-IR): design and rationale from the International Valvular Surgery Study Group (IVSSG). Annals of cardiothoracic surgery, 4(2), 131-9. https://doi.org/10.3978/j.issn.2225-319X.2015.02.05
Di Eusanio, Marco, et al. "Sutureless Aortic Valve Replacement International Registry (SU-AVR-IR): design and rationale from the International Valvular Surgery Study Group (IVSSG)." Annals of cardiothoracic surgery vol. 4,2 (2015): 131-9. doi: https://doi.org/10.3978/j.issn.2225-319X.2015.02.05
Di Eusanio M, Phan K, Bouchard D, Carrel TP, Dapunt OE, Di Bartolomeo R, Eichstaedt HC, Fischlein T, Folliguet T, Gersak B, Glauber M, Haverich A, Misfeld M, Oberwalder PJ, Santarpino G, Shrestha ML, Solinas M, Vola M, Alamanni F, Albertini A, Bhatnagar G, Carrier M, Clark S, Collart F, Kappert U, Kocher A, Meuris B, Mignosa C, Ouda A, Pelletier M, Rahmanian PB, Reineke D, Teoh K, Troise G, Villa E, Wahlers T, Yan TD. Sutureless Aortic Valve Replacement International Registry (SU-AVR-IR): design and rationale from the International Valvular Surgery Study Group (IVSSG). Ann Cardiothorac Surg. 2015 Mar;4(2):131-9. doi: 10.3978/j.issn.2225-319X.2015.02.05. PMID: 25870808; PMCID: PMC4384261.
Copy Download .nbib Format: NLM
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Science advances

Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J.
PMID: 26601252
Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-term disease control, but relapse invariably occurs within months....

Cite
Green AS, Maciel TT, Hospital MA, et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv. 2015;1(8):e1500221doi: 10.1126/sciadv.1500221.
Green, A. S., Maciel, T. T., Hospital, M. A., Yin, C., Mazed, F., Townsend, E. C., Pilorge, S., Lambert, M., Paubelle, E., Jacquel, A., Zylbersztejn, F., Decroocq, J., Poulain, L., Sujobert, P., Jacque, N., Adam, K., So, J. C., Kosmider, O., Auberger, P., Hermine, O., Weinstock, D. M., Lacombe, C., Mayeux, P., Vanasse, G. J., Leung, A. Y., Moura, I. C., Bouscary, D., & Tamburini, J. (2015). Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Science advances, 1(8), e1500221. https://doi.org/10.1126/sciadv.1500221
Green, Alexa S, et al. "Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia." Science advances vol. 1,8 (2015): e1500221. doi: https://doi.org/10.1126/sciadv.1500221
Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep. PMID: 26601252; PMCID: PMC4643770.
Copy Download .nbib Format: NLM
Invited Commentary on Fuzellier et al. Ann Thorac Surg 2016;101:1716-23.

The Annals of thoracic surgery

Ben Ali W, Bouchard D, Perrault LP.
PMID: 27211985
Ann Thorac Surg. 2016 Jun;101(6):e213. doi: 10.1016/j.athoracsur.2015.11.033.

No abstract available.

Cite
Ben Ali W, Bouchard D, Perrault LP. Invited Commentary on Fuzellier et al. Ann Thorac Surg 2016;101:1716-23. Ann Thorac Surg. 2016;101(6):e213doi: 10.1016/j.athoracsur.2015.11.033.
Ben Ali, W., Bouchard, D., & Perrault, L. P. (2016). Invited Commentary on Fuzellier et al. Ann Thorac Surg 2016;101:1716-23. The Annals of thoracic surgery, 101(6), e213. https://doi.org/10.1016/j.athoracsur.2015.11.033
Ben Ali, Walid, et al. "Invited Commentary on Fuzellier et al. Ann Thorac Surg 2016;101:1716-23." The Annals of thoracic surgery vol. 101,6 (2016): e213. doi: https://doi.org/10.1016/j.athoracsur.2015.11.033
Ben Ali W, Bouchard D, Perrault LP. Invited Commentary on Fuzellier et al. Ann Thorac Surg 2016;101:1716-23. Ann Thorac Surg. 2016 Jun;101(6):e213. doi: 10.1016/j.athoracsur.2015.11.033. PMID: 27211985.
Copy Download .nbib Format: NLM
Relapsed, Refractory, or Advanced Hodgkin Lymphoma: A Single-Center Experience.

Clinical lymphoma, myeloma & leukemia

Boilève A, Grignano E, Bouscary D, Fourquet A, Deau-Fischer B, Kirova Y.
PMID: 32933880
Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e27-e31. doi: 10.1016/j.clml.2020.08.015. Epub 2020 Aug 22.

PURPOSE: To assess the treatment and outcomes of patients with relapsed, refractory, or advanced Hodgkin lymphoma treated with consolidation or salvage radiotherapy.PATIENTS AND METHODS: We studied all patients diagnosed with this profile treated by radiotherapy in our center between...

Cite
Boilève A, Grignano E, Bouscary D, et al. Relapsed, Refractory, or Advanced Hodgkin Lymphoma: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2020;21(1):e27-e31doi: 10.1016/j.clml.2020.08.015.
Boilève, A., Grignano, E., Bouscary, D., Fourquet, A., Deau-Fischer, B., & Kirova, Y. (2021). Relapsed, Refractory, or Advanced Hodgkin Lymphoma: A Single-Center Experience. Clinical lymphoma, myeloma & leukemia, 21(1), e27-e31. https://doi.org/10.1016/j.clml.2020.08.015
Boilève, Alice, et al. "Relapsed, Refractory, or Advanced Hodgkin Lymphoma: A Single-Center Experience." Clinical lymphoma, myeloma & leukemia vol. 21,1 (2021): e27-e31. doi: https://doi.org/10.1016/j.clml.2020.08.015
Boilève A, Grignano E, Bouscary D, Fourquet A, Deau-Fischer B, Kirova Y. Relapsed, Refractory, or Advanced Hodgkin Lymphoma: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e27-e31. doi: 10.1016/j.clml.2020.08.015. Epub 2020 Aug 22. PMID: 32933880.
Copy Download .nbib Format: NLM
Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes.

Environment international

Haenni M, Dagot C, Chesneau O, Bibbal D, Labanowski J, Vialette M, Bouchard D, Martin-Laurent F, Calsat L, Nazaret S, Petit F, Pourcher AM, Togola A, Bachelot M, Topp E, Hocquet D.
PMID: 34923370
Environ Int. 2021 Dec 16;159:107047. doi: 10.1016/j.envint.2021.107047. Epub 2021 Dec 16.

Antimicrobial resistance (AMR) is a major global public health concern, shared by a large number of human and animal health actors. Within the framework of a One Health approach, actions should be implemented in the environmental realm, as well...

Cite
Haenni M, Dagot C, Chesneau O, et al. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environ Int. 2021;159:107047doi: 10.1016/j.envint.2021.107047.
Haenni, M., Dagot, C., Chesneau, O., Bibbal, D., Labanowski, J., Vialette, M., Bouchard, D., Martin-Laurent, F., Calsat, L., Nazaret, S., Petit, F., Pourcher, A. M., Togola, A., Bachelot, M., Topp, E., & Hocquet, D. (2021). Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environment international, 159107047. https://doi.org/10.1016/j.envint.2021.107047
Haenni, Marisa, et al. "Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes." Environment international vol. 159 (2021): 107047. doi: https://doi.org/10.1016/j.envint.2021.107047
Haenni M, Dagot C, Chesneau O, Bibbal D, Labanowski J, Vialette M, Bouchard D, Martin-Laurent F, Calsat L, Nazaret S, Petit F, Pourcher AM, Togola A, Bachelot M, Topp E, Hocquet D. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environ Int. 2021 Dec 16;159:107047. doi: 10.1016/j.envint.2021.107047. Epub 2021 Dec 16. PMID: 34923370.
Copy Download .nbib Format: NLM
Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes.

Environment international

Haenni M, Dagot C, Chesneau O, Bibbal D, Labanowski J, Vialette M, Bouchard D, Martin-Laurent F, Calsat L, Nazaret S, Petit F, Pourcher AM, Togola A, Bachelot M, Topp E, Hocquet D.
PMID: 34923370
Environ Int. 2021 Dec 16;159:107047. doi: 10.1016/j.envint.2021.107047. Epub 2021 Dec 16.

Antimicrobial resistance (AMR) is a major global public health concern, shared by a large number of human and animal health actors. Within the framework of a One Health approach, actions should be implemented in the environmental realm, as well...

Cite
Haenni M, Dagot C, Chesneau O, et al. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environ Int. 2021;159:107047doi: 10.1016/j.envint.2021.107047.
Haenni, M., Dagot, C., Chesneau, O., Bibbal, D., Labanowski, J., Vialette, M., Bouchard, D., Martin-Laurent, F., Calsat, L., Nazaret, S., Petit, F., Pourcher, A. M., Togola, A., Bachelot, M., Topp, E., & Hocquet, D. (2021). Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environment international, 159107047. https://doi.org/10.1016/j.envint.2021.107047
Haenni, Marisa, et al. "Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes." Environment international vol. 159 (2021): 107047. doi: https://doi.org/10.1016/j.envint.2021.107047
Haenni M, Dagot C, Chesneau O, Bibbal D, Labanowski J, Vialette M, Bouchard D, Martin-Laurent F, Calsat L, Nazaret S, Petit F, Pourcher AM, Togola A, Bachelot M, Topp E, Hocquet D. Environmental contamination in a high-income country (France) by antibiotics, antibiotic-resistant bacteria, and antibiotic resistance genes: Status and possible causes. Environ Int. 2021 Dec 16;159:107047. doi: 10.1016/j.envint.2021.107047. Epub 2021 Dec 16. PMID: 34923370.
Copy Download .nbib Format: NLM
Correction to: Prevalence of anal symptoms in general practice: a prospective study.

BMC family practice

Tournu G, Abramowitz L, Couffignal C, Juguet F, Sénéjoux A, Berger S, Wiart AL, Bernard M, Provost F, Moult HP, Bouchard D, Aubert JP.
PMID: 30654761
BMC Fam Pract. 2019 Jan 17;20(1):14. doi: 10.1186/s12875-019-0905-z.

Following publication of the original article [1], the authors reported an error to one of the 'study groups' in the authorship section.

Cite
Tournu G, Abramowitz L, Couffignal C, et al. Correction to: Prevalence of anal symptoms in general practice: a prospective study. BMC Fam Pract. 2019;20(1):14doi: 10.1186/s12875-019-0905-z.
Tournu, G., Abramowitz, L., Couffignal, C., Juguet, F., Sénéjoux, A., Berger, S., Wiart, A. L., Bernard, M., Provost, F., Moult, H. P., Bouchard, D., Aubert, J. P. (2019). Correction to: Prevalence of anal symptoms in general practice: a prospective study. BMC family practice, 20(1), 14. https://doi.org/10.1186/s12875-019-0905-z
Tournu, Géraldine, et al. "Correction to: Prevalence of anal symptoms in general practice: a prospective study." BMC family practice vol. 20,1 (2019): 14. doi: https://doi.org/10.1186/s12875-019-0905-z
Tournu G, Abramowitz L, Couffignal C, Juguet F, Sénéjoux A, Berger S, Wiart AL, Bernard M, Provost F, Moult HP, Bouchard D, Aubert JP. Correction to: Prevalence of anal symptoms in general practice: a prospective study. BMC Fam Pract. 2019 Jan 17;20(1):14. doi: 10.1186/s12875-019-0905-z. PMID: 30654761; PMCID: PMC6335827.
Copy Download .nbib Format: NLM
Showing 109 to 120 of 173 entries